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ABSTRACT
Introduction Ensuring universal availability and 
accessibility of medicines and supplies is critical for 
national health systems to equitably address population 
health needs. In sub- Saharan Africa (SSA), this is a 
recognised priority with multiple medicines pricing 
policies enacted. However, medicine prices have remained 
high, continue to rise and constrain their accessibility. In 
this systematic review, we aim to identify and analyse 
experiences of implementation of medicines pricing 
policies in SSA. Our ambition is for this evidence to 
contribute to improved implementation of medicines 
pricing policies in SSA.
Methods and analysis We will search: Medline, Web 
of Science, Scopus, Global Health, Embase, Cairn.Info 
International Edition, Erudit and African Index Medicus, the 
grey literature and reference from related publications. 
The searches will be limited to literature published from 
the year 2000 onwards that is, since the start of the 
Millennium Development Goals.
Published peer- reviewed studies of implementation of 
medicines pricing policies in SSA will be eligible for 
inclusion. Broader policy analyses and documented 
experiences of implementation of other health policies will 
be excluded. The team will collaboratively screen titles and 
abstracts, then two reviewers will independently screen 
full texts, extract data and assess quality of the included 
studies. Disagreements will be resolved by discussion or 
a third reviewer. Data will be extracted on approaches 
used for policy implementation, actors involved, evidence 
used in decision making and key contextual influences on 
policy implementation. A narrative approach will be used 
to synthesise the data. Reporting will be informed by the 
Preferred Reporting Items for Systematic Reviews and 
Meta- Analyses Protocols guideline.
Ethics and dissemination No ethics approvals are 
required for systematic reviews.
Results will be disseminated through academic 
publications, policy briefs and presentations to national 
policymakers in Ghana and mode widely across countries 
in SSA.
PROSPERO registration number CRD42020178166.
INTRODUCTION
The current agenda of Universal Health 
Coverage highlights the importance of access 
to safe, quality and affordable medicines as 
its key driver.1–3 Increasing access to essential 
medicines through medicines pricing inter-
ventions is an issue of current health policy 
discourses.4 5 In response, various policy 
initiatives have evolved to regulate medicine 
pricing and improve access.
Globally, different medicine pricing models 
and strategies exist. These include: generic 
or biosimilar price linking to originator 
products, non- proprietary prescribing and 
generic substitutions, tendering and pooled 
procurements, internal reference pricing, 
external price referencing or international 
price comparisons and managed- entry agree-
ments.6–8 Implementation of these medi-
cine pricing policies may be dependent on 
in- country manufacturing capacity, pricing 
levels of the medicines, whether medicines 
Strengths and limitations of this study
 ► This systematic review protocol follows the Preferred 
Reporting Items for Systematic Reviews and Meta- 
Analyses Protocols guidelines.
 ► The review addresses a gap in the current knowl-
edge of the determinants and outcomes of success-
ful implementation of medicines pricing policies in 
sub- Saharan Africa (SSA).
 ► The focus on SSA will help with transferability of les-
sons across the different countries within the region, 
though this may lead to omission of important ex-
periences for example from Asia and Latin America 
and may limit transferability of lessons outside the 
SSA.
 ► The search will be restricted to peer- reviewed pub-
lished articles and grey literature, thus, relevant the-
ses and conference abstracts are likely to be omitted 
and may affect the depth of evidence on the topic.
 ► The narrative synthesis approach reflects the nature 
of published evidence on the topic of policy imple-
mentation with no meta- analysis possible, and is a 
potential limitation of this review.
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are generic or branded, and whether medicines are for 
outpatient or inpatient services.9
Many of these medicine pricing policies are being 
implemented in high- income countries. However, unlike 
in high- income countries, low- income and middle- 
income countries have less regulated and developed 
pharmaceutical markets and have different challenges 
in distribution and production.1 In light of this, multiple 
medicine pricing models and strategies are required to 
achieve equitable access to safe, quality and affordable 
medicines,10 particularly in sub- Saharan African (SSA) 
countries.10
Rationale
Ensuring availability and accessibility of medicines is an 
important mechanism by which national health systems 
can equitably address health needs of their populations, 
including the poorest and the most vulnerable. In SSA, 
this is a recognised policy priority. For example, in the 
last two decades different medicines pricing policies 
were implemented in South Africa11 12 and between 
2012 and 2017, the Government of Ghana introduced 
four policies to improve access to medicines through 
medicine price regulation, and ultimately, health 
outcomes and quality of life. These policies are currently 
at different stages of their implementation and despite 
these efforts, medicine prices have remained high and 
continue to rise, making them inaccessible to a large 
proportion of populations. This raises questions as to 
why and how these policies are failing to achieve the 
desired outcomes.
In this systematic review, we will explore the effective-
ness of implementation of medicines pricing policies 
in the SSA context. We want to identify which policies 
have been implemented and then explore three broad 
dimensions of their implementation. First, we want to 
understand what happened, that is, identify evidence on 
effective implementations of medicines pricing policies 
reflected in a reduction in prices and improvement in 
access to medicines and subsequently healthcare. Second, 
we want to understand how it happened, that is, we want 
to identify and unpack the implementation processes and 
approaches deployed in terms of their timing, partici-
pation of actors and role of evidence. Third, we want to 
understand why it happened. We want to identify and 
synthesise key reported facilitators and barriers to the 
implementation and understand how they affected the 
implementation of these policies within their respective 
contexts.
Aim and objectives
In this systematic review, we will address the following 
overall question: what are the key determinants of imple-
mentation of medicines pricing policies in SSA countries? 
More specifically, we will answer four questions:
1. Which medicines pricing policies have been imple-
mented in SSA and what are their key elements?
2. How have these policies been implemented (in rela-
tion to implementation approaches, processes, in-
volvement of actors, role of evidence, etc)?
3. Which key facilitators and barriers affected the imple-
mentation of medicines pricing policies, and how?
4. Which implementation of medicines pricing policies 
in SSA are effective (in relation to reducing prices of 
medicines and improving access to services)?
This review is being undertaken during April 2020–May 
2021 as part of the project on ‘Improving equitable access 
to essential medicines in Ghana through bridging the 
gaps in implementing medicines pricing policy’ (AMIPS 
project)—an National Institute for Health Research 
(NIHR) funded award received jointly by the University 
of Leeds, University of Ghana and the Ghana Health 
Service. The results of this review will be combined 
with results of policy analyses in Ghana and will inform 
engagements with key stakeholders on improving the 
implementation of the current policies and identifica-
tion of future research and development priorities. Our 
ambition is for evidence from this review to contribute to 
improved implementation of medicines pricing policies 
across countries of SSA.
This protocol follows the Preferred Reporting Items for 
Systematic Reviews and Meta- Analyses- Protocols (PRIS-
MA- P) guidelines13 and a PRISMA- P checklist is available 




We will include empirical studies including Randomised 
Controlled Trials, quasi- experimental studies and cohort 
and cross- sectional studies. Reviews (scoping reviews, 
meta- syntheses, realist syntheses) will also be included 
and individual primary studies from the systematic 
reviews will be manually included as empirical literature. 
We will exclude opinion pieces and conceptual/theoret-
ical publications which do not report documented empir-
ical data from either primary studies or reviews.
Specific inclusion criteria will be: (1) focus on the 
medicines pricing policies that is, policies, strategies, 
interventions or plans which aim to improve affordability 
of medicines in the country. The link to improvements in 
access to healthcare may be implicit and is not a require-
ment; (2) focus on policy implementation, that is, either 
as part of the whole policy process (agenda- setting, devel-
opment, implementation) or as an exclusive focus; (3) 
SSA country contexts, that is, either as part of the compar-
ative studies or as a sole focus; (4) studies which were 
published since the agenda of Millennium Development 
Goals (MDGs) was initiated shortly before 2000 and (5) 
papers with relevant information available for analysis.
Specific exclusion criteria are: (1) policy analyses which 
focus solely on policy agenda- setting and development 
stages of the policy process; (2) studies from high- income 
country contexts and outside SSA; (3) studies conducted 
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2 years or more prior to 2000 but published after 2000 
will be excluded in consideration of MDGs and Sustain-
able Development Goals (SDGs) agenda which started 
in 2000; (4) papers in languages where we are unable to 
have the resources for translation (the team has access to 
French, Spanish and Russian- speaking researchers) and 
(5) papers with no full text available for analysis.
Participants
The participants to be covered in this review will be: 
policy- makers, implementers, service providers, patients 
and beneficiaries of successful implementation of medi-
cines pricing policies (of any gender, age, ethnicity, socio-
economic group, health status or urban–rural residence).
Interventions
Implementation of medicines pricing policies, that is, 
policies, strategies, interventions or plans which aim to 
improve affordability of medicines in the country.
Comparison
No comparison or control is applicable to this study.
Outcomes
Successful implementation will be measured as reduction 
in medicines prices, and improved access to medicines 
along the supply chain. Any studies describing unsuc-




We will search the following databases: Medline (1946–
present), Web of Science (1990–present), Scopus 
(1823–present), Global Health (1973–present), Embase 
(1947–present), Cairn.Info International Edition (all 
available years), Erudit (all available years) and African 
Index Medicus (all available years). The Medline search 
strategy is available as an online supplemental file. The 
search strategies will incorporate index terms from 
Medical Subject Headings (MeSH) and text words for the 
search concepts:
1. Sub- Saharan African Countries. This will include 
terms/synonyms for sub- Saharan Africa AND list of in-
dividual countries in the region.
2. Drug/Medicines pricing. This will include terms/
synonyms for: medicines / pharmaceuticals / drugs / 
prescriptions AND pricing / cost / affordability / fees 
/ purchase / rebate(s) / tariffs / incentives / bench-
marking / reference pricing / payment / spend* / ex-
penditure / subsid* / procurement.
3. Policy. This will include terms/synonyms for: policy / 
strategy / plan / framework / regulations / guidelines 
/ rules / intervention / tax / exemption.
4. Implementation. This will include terms / synonyms 
for: Implementing / Implement(s) / Implementation 
approach(es) / Process(es) / Facilitator(s) / Barrier(s) 
/ Factors / Determinants / context.
The searches will be limited to the literature published 
from the year 2000 and onwards. This is in consider-
ation of the Millennium Development Goals agenda 
which started in 2000 with a clear focus on improving 
access to medicines and services. We will follow up on the 
references to the individual studies as required. We will 
manually search for the included references in relevant 
retrieved reviews (systematic reviews, scoping reviews, 
meta- syntheses, realist syntheses) for additional relevant 
studies for inclusion. In addition, we will search grey 
literature including global development websites: World 
Health Organisation's (WHO) Institutional Repository 
for Information Sharing (IRIS), World Bank, Knowledge, 
Evidence and Learning for Development (K4D) reposi-
tory, Gates Foundation and contacts with experts in the 
field.
Data management
We will upload all references identified through searches 
(electronic database and additional searches) into 
Endnote version X9. Once duplicates are removed, 
the remaining references will be exported into Rayyan 
(https:// rayyan. qcri. org/ welcome), an online free 
systematic review tool for screening.
Screening
Titles and abstracts will be divided up across the review 
team and screened individually for eligibility using 
prespecified eligibility criteria flow chart, which is avail-
able in an online supplemental file. At least 20% of 
individually reviewed titles and abstracts will then be cross- 
checked by at least two members of the team. Full texts 
will be obtained for all the potentially relevant studies 
and screened by two members of the team independently, 
and disagreements will be resolved through discussion. 
Where necessary, a third member of the team will engage 
to help resolve disagreements.
Data extraction
The following data will be extracted by two members of 
the review team into an appropriate data extraction form:
 ► Article information (full citation, year study was 
conducted, study type, setting / country).
 ► Medicine pricing policies studied (including which 
key elements the policies included).
 ► Documented effects on prices of medicines (including 
how identified and reported).
 ► Effects on access to medicines (including how identi-
fied and reported).
 ► Effects on access to healthcare (including how identi-
fied and reported).
 ► Implementation approach (including processes, 
actors involved and their roles and evidence used to 
inform implementation).
 ► Key influences on policy implementation (including 
facilitators and constraints and how they affected 
implementation).
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Quality assessment and risk of bias
Quality of each included study will be appraised. We 
will use validated quality assessment tools and the crit-
ical appraisal tools for relevant studies (qualitative and 
quantitative research) from the Joanna Briggs Institute 
https:// joannabriggs. org/ ebp/ critical_ appraisal_ tools. 
While at this point, we do not intend to change the actual 
criteria, the interpretation and application of the tools 
will be within the context of our study which focuses on 
key determinants of effective implementation of medi-
cines pricing policies in SSA context. For example, 
clarity of focus will be assessed in relation to how the 
different aspects of policy implementation (processes, 
use of evidence, involvement of actors) are identified and 
consistently used in the reviewed papers.
A careful assessment of risk of bias in the included 
studies will be performed by two reviewers, who will first 
independently assess the quality of each study against 
each criterion. Results will be shared and agreed, and 
any disagreements will be addressed through engaging a 
third reviewer.
Data synthesis and interpretation
Strategy for data synthesis
The main outcome in our study is the medicine pricing 
policy implementation. Policy implementation is typically 
done within a single country, but where the same policy is 
implemented in different countries, the analysis will take 
the specific context of the country into consideration.
In exploring the policy implementation, we will employ 
established policy theories and frameworks such as Walt 
and Gilson’s policy triangle,14 Baumgartner and Jones’s 
punctuated equilibrium15 and Lipsky’s street- level bureau-
cracy,16 and will also draw on further theories and frame-
works developed or adapted within the reviewed papers.
Where possible, we will compare the effects of the poli-
cies in a quantitative synthesis. We anticipate, however, 
that the heterogeneity of reporting of outcomes and 
of context may make it impossible to conduct a meta- 
analysis. In such a situation we will focus on narrative 
synthesis.
While using qualitative or narrative synthesis approach,17 
data related to the medicines pricing policies will be 
extracted from the Introduction, Methods and possibly 
Results sections. Data on the effects of policy implementa-
tion and the policy implementation approaches, and key 
influences will be extracted from the Results and Discus-
sion sections. Extracted data will be analysed thematically 
and will be structured around the specific questions of 
the review.
The interpretation of the results will follow the iden-
tified themes for each review question. For example, in 
answering the third review question we will divide the 
factors into facilitators and constraints and potentially 
will further subdivide them by their nature (eg, commu-
nity issues, health systems issues, wider socioeconomic 
influences).
At the moment, we are not planning analysis of 
subgroups or subsets. However, depending on the 
breadth of extracted data we may consider subgroups 
such as geographical region (West Africa, East Africa, 
Southern Africa), setting (urban, rural) or categories of 
implementers (health facilities, pharmacies).
The cumulative strength of body of evidence will be 
assessed across the risk of bias and consistency, drawing 
on relevant approaches such as Grading of Recom-
mendations Assessment, Development and Evaluation 
(GRADE).
Patient and public involvement
No patient involved.
ETHICS AND DISSEMINATION
Ethics approvals are not required for systematic reviews. 
However, ethics approvals for the wider AMIPS study 
within which this review is being undertaken have been 
granted by the ethics committees from the Ghana Health 
Service (ref GHS- ERC006/02/20) and the University of 
Leeds School of Medicine (ref MREC 19–060).
We will disseminate results through academic papers 
and stakeholder workshops in Ghana and other SSA 
countries where possible. In Ghana, the review results will 
be complemented by reviews of policy documents. The 
findings of this review will also be presented at scientific 
conferences such as the biannual Global Symposia on 
Health Systems Research and Thematic Working Groups 
of the Health Systems Global.
The results of this review will inform empirical inves-
tigations of implementation of medicines pricing poli-
cies in Ghana through the in- depth interviews and focus 
groups, and engagements and consultations with policy- 
makers on seeking ways of further improving the imple-
mentation of medicines pricing policies in Ghana.
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Title: Implementation of medicines pricing policies in sub-Saharan Africa: protocol for a systematic 
review 
 
PRISMA-P (preferred reporting items for systematic review and meta-analysis protocols) 2015 
checklist: recommended items to address in a systematic review protocol 
 





Title:      
 Identification   1a Identify the report as a protocol of a 
systematic review 
Y 1 1-2 
 Update   1b If the protocol is for an update of a 
previous systematic review, identify as 
such 
n/a n/a n/a 
Registration   2 If registered, provide the name of the 
registry (such as PROSPERO) and 
registration number 
Y 2 67-68 
Authors:      
 Contact 3a Provide name, institutional affiliation, 
e-mail address of all protocol authors; 
provide physical mailing address of 
corresponding author 
Y 1 6-26 
 Contributions 3b Describe contributions of protocol 
authors and identify the guarantor of 
the review 
Y 9 297-299 
Amendments 4 If the protocol represents an 
amendment of a previously completed 
or published protocol, identify as such 
and list changes; otherwise, state plan 
for documenting important protocol 
amendments 
n/a n/a n/a 
Support:      
 Sources 5a Indicate sources of financial or other 
support for the review 
Y 9 302-304 
 Sponsor 5b Provide name for the review funder 
and/or sponsor 
Y 9 302-304 
 Role of sponsor or 
funder 
5c Describe roles of funder(s), sponsor(s), 
and/or institution(s), if any, in 
developing the protocol 
Y 9 304-306 
Introduction      
 Rationale 6 Describe the rationale for the review in 
the context of what is already known 
Y 4 108-126 
 Objectives 7 Provide an explicit statement of the 
question(s) the review will address 
with reference to participants, 
interventions, comparators, and 
outcomes (PICO) 
Y 5 129-147 
Methods 
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Eligibility criteria 8 Specify the study characteristics (such 
as PICO, study design, setting, time 
frame) and report characteristics (such 
as years considered, language, 
publication status) to be used as 
criteria for eligibility for the review 
Y 5-6 153-186 
Information sources 9 Describe all intended information 
sources (such as electronic databases, 
contact with study authors, trial 
registers or other grey literature 
sources) with planned dates of 
coverage 
Y 5 154-158 
Search strategy 10 Present draft of search strategy to be 
used for at least one electronic 
database, including planned limits, 
such that it could be repeated 
Y 6-7 189-212 
Study records:      
 Data management 11a Describe the mechanism(s) that will be 
used to manage records and data 
throughout the review 
Y 7 214-217 
 Selection process 11b State the process that will be used for 
selecting studies (such as two 
independent reviewers) through each 
phase of the review (that is, screening, 
eligibility and inclusion in meta-
analysis) 
Y 7 219-224 
 Data collection 
process 
11c Describe planned method of extracting 
data from reports (such as piloting 
forms, done independently, in 
duplicate), any processes for obtaining 
and confirming data from investigators 
Y 7 226-236 
Data items 12 List and define all variables for which 
data will be sought (such as PICO 
items, funding sources), any pre-
planned data assumptions and 
simplifications 
Y 7-8 228-236 
Outcomes and 
prioritization 
13 List and define all outcomes for which 
data will be sought, including 
prioritization of main and additional 
outcomes, with rationale 
Y 8 251-273 
Risk of bias in individual 
studies 
14 Describe anticipated methods for 
assessing risk of bias of individual 
studies, including whether this will be 
done at the outcome or study level, or 
both; state how this information will 
be used in data synthesis 
Y 7 237-248 
Data synthesis 15a Describe criteria under which study 
data will be quantitatively synthesised 
n/a n/a n/a 
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 15b If data are appropriate for quantitative 
synthesis, describe planned summary 
measures, methods of handling data 
and methods of combining data from 
studies, including any planned 
exploration of consistency (such as I2, 
Kendall’s τ) 
n/a n/a n/a 
 15c Describe any proposed additional 
analyses (such as sensitivity or 
subgroup analyses, meta-regression) 
n/a n/a n/a 
 15d If quantitative synthesis is not 
appropriate, describe the type of 
summary planned 
Y 8 261-269 
Meta-bias(es) 16 Specify any planned assessment of 
meta-bias(es) (such as publication bias 
across studies, selective reporting 
within studies) 
Y 8 258-260 
Confidence in cumulative 
evidence 
17 Describe how the strength of the body 
of evidence will be assessed (such as 
GRADE) 
Y 8 266-275 
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Along with Medline we intend to search the following databases:  
African Index Medicus (via WHO Global Health Index Medicus) all available years; Embase (Ovid) 
1996 present; Global Health (Ovid) 1973 to present; Scopus (Elsevier B.V.) 1823 – Present; Web of 
Science Core Collection: Citation Indexes (Clarivate Analytics) 1900-present;. We will also search for 
grey literature and French articles in the following; Cairn International (Cairn Info) all available years;  
Erudit (University of Montreal ???) all available years; IRIS Institutional Repository for Information 
Sharing (WHO) all available years and World Bank Group Research and Publications 
 
Sample Medline strategy 
Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily 
<1946 to April 23, 2020> 
Search Strategy: 
-------------------------------------------------------------------------------- 
1     exp "Africa South of the Sahara"/ (205870) 
2     (angola* or benin* or botswana* or "burkina faso" or burundi*).ti,ab,in,kf. (17906) 
3     ("cabo verde*" or "cape verde*" or cameroon* or "central africa*" or chad or cormoros or 
congo* or "ivory coast" or "cote d'ivoire" or djibouti).ti,ab,in,kf. (45277) 
4     (guinea* or eritrea* or eswatini* or swaziland* or ethiopia* or gabon* or gambia* or ghana* or 
guinea*).ti,ab,in,kf. (158364) 
5     (kenya* or lesotho* or liberia* or madagasca* or malawi* or mali or mauritania* or mauritius or 
mozambique*).ti,ab,in,kf. (55553) 
6     (namibia* or niger or nigeria* or rwanda*).ti,ab,in,kf. (67659) 
7     ("sao tome" or principe* or senegal* or seychelles or "sierra leone*" or somali* or "south 
africa*" or sudan*).ti,ab,in,kf. (132358) 
8     (tanzania* or togo* or uganda* or zambia* or zaire* or zimbabw*).ti,ab,in,kf. (50798) 
9     (africa* adj2 ("sub sahara*" or "south* sahara*")).ti,ab,in,kf. (23957) 
10     or/1-9 [sub-saharan africa] (519682) 
11     Drug Costs/ (15924) 
12     ((price? or pricing) adj5 (medicine? or drug? or prescription? or pharmaceutical*)).tw,kw. 
(4558) 
13     ((cost or costs) adj5 (medicine? or drug? or prescription? or pharmaceutical*)).tw,kw. (18930) 
14     (afford* adj5 (medicine? or drug? or prescription? or pharmaceutical*)).tw,kw. (1929) 
15     (reimburs* adj5 (medicine? or drug? or prescription? or pharmaceutical*)).tw,kw. (2099) 
16     (generic* adj5 (medicine? or drug? or prescription? or pharmaceutical*)).tw,kw. (4521) 
17     exp fees, pharmaceutical/ (2413) 
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18     ((purchas* or procur* or expenditure*) adj5 (medicine? or drug? or prescription? or 
pharmaceutical*)).tw,kw. (4913) 
19     ((subsid* or tariff* or incentive* or containment or transparency) adj5 (medicine? or drug? or 
prescription? or pharmaceutical*)).tw,kw. (2141) 
20     ((fee or fees or rebate* or payment* or spend* or saving*) adj5 (medicine? or drug? or 
prescription? or pharmaceutical*)).tw,kw. (4006) 
21     ((benchmark* or cost-plus) adj12 (medicine? or drug? or prescription? or 
pharmaceutical*)).tw,kw. (641) 
22     "low* price* generic*".tw,kw. (76) 
23     (essential adj2 (drug* or medicine*)).tw,kw. (3434) 
24     Drugs, Essential/ (835) 
25     (access* adj3 (medicine? or drug? or prescription? or pharmaceutical*)).tw,kw. (5991) 
26     Economics, Pharmaceutical/ (2927) 
27     (pharma* adj2 economic*).tw,kw. (833) 
28     pharmacoeconomic*.tw,kw. (3898) 
29     or/11-28 [drug pricing] (58841) 
30     exp policy/ (155119) 
31     Government Regulation/ (21073) 
32     exp Legislation, Drug/ (32091) 
33     ((drug* or medicine* or pharmaceutical* or prescription* or health*) adj7 (guideline* or 
guidance or policy or policies or law or regulat* or rule* or legislat* or control* or strateg* or 
framework*)).tw,kw. (538082) 
34     (tax or taxes or exemption*).tw,kw. (17307) 
35     ((drug* or medicine* or pharmaceutical* or prescription* or health*) adj7 (intervention* or 
plan* or program*)).tw,kw. (256052) 
36     or/30-35 [policy concept -all] (917754) 
37     10 and 29 and 36 [SSA and policy ] (1190) 
38     Health Plan Implementation/ (5829) 
39     Program Evaluation/ (62240) 
40     (barrier* or facilitator* or challenge* or motivator*).tw,kw. (923252) 
41     (implement* or approach* or process*).tw,kw. (3962356) 
42     (factor* or determinant* or context*).tw,kw. (3829825) 
43     "scal* up".tw,kw. (19228) 
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44     adopt*.tw,kw. (243593) 
45     or/38-44 [implementation] (7698904) 
46     10 and 29 and 36 and 45 (763) 
47     limit 46 to yr="2000 -Current" (652) 
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Step 5: Was the study conducted 
within MDGs? 
 Study conducted since 1998? 
 Published since 2000?  
Wrong period – EXCLUDE 
Label: before MDGs 
Step 4: Does the study focus on a 
 Country in sub-Saharan Africa? 
 See list of countries in SSA 
NO (agenda-setting or 
policy development) 
Wrong topic - EXCLUDE 
Label: not implementation 
Step 1: Does the study focus on 
 Drug/Medicines pricing? 
 Drug/Medicine pricing policy? 
 Reference pricing? 
 Pharmaceuticals / drugs / 
prescriptions cost / purchase? 
 Affordability / fees / rebate / 
tariffs / incentives / payment? 
 Benchmarking /expenditure / 





Wrong topic - EXCLUDE  
Label: not medicines pricing 
policy 
Step 6: Is this empirical study or 
systematic review? 
 RCT, quasi-experimental, 
cohort, cross-sectional? 
Wrong study type – EXCLUDE 





Step 2: Does study focus on Policy  
  Implementation? 
 Policy / strategy / plan / 
Guideline 
 Implementation approach / 
Process? 
 Facilitators / Barriers / Factors 






















































Wrong setting  
EXCLUDE 
Label: not SSA 
NO 
NO (e.g., opinion or 
conceptual) 
TO BE DECIDED 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open
 doi: 10.1136/bmjopen-2020-044293:e044293. 11 2021;BMJ Open, et al. Mirzoev T
